Nintedanib (BIBF 1120) in Mesothelioma
Read time: 1 mins
Last updated:22nd Jul 2013
This is an exploratory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.
|Study start date||2013-07-22|